Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.

TitleTumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.
Publication TypeJournal Article
Year of Publication2022
AuthorsSchad SE, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, Caushi JX, Malandro N, Zappasodi R, Gigoux M, Hirschhorn D, Budhu S, Amisaki M, Arniella M, Redmond D, Chaft J, Forde PM, Gainor JF, Hellmann MD, Balachandran V, Shah S, Smith KN, Pardoll D, Elemento O, Wolchok JD, Merghoub T
JournalJ Exp Med
Volume219
Issue6
Date Published2022 Jun 06
ISSN1540-9538
KeywordsAnimals, CD4 Antigens, CD4-Positive T-Lymphocytes, CD8 Antigens, CD8-Positive T-Lymphocytes, Cell Differentiation, Cell Lineage, Melanoma, Mice, T-Lymphocyte Subsets
Abstract

Transcription factors ThPOK and Runx3 regulate the differentiation of "helper" CD4+ and "cytotoxic" CD8+ T cell lineages respectively, inducing single positive (SP) T cells that enter the periphery with the expression of either the CD4 or CD8 co-receptor. Despite the expectation that these cell fates are mutually exclusive and that mature CD4+CD8+ double positive (DP) T cells are present in healthy individuals and augmented in the context of disease, yet their molecular features and pathophysiologic role are disputed. Here, we show DP T cells in murine and human tumors as a heterogenous population originating from SP T cells which re-express the opposite co-receptor and acquire features of the opposite cell type's phenotype and function following TCR stimulation. We identified distinct clonally expanded DP T cells in human melanoma and lung cancer by scRNA sequencing and demonstrated their tumor reactivity in cytotoxicity assays. Our findings indicate that antigen stimulation induces SP T cells to differentiate into DP T cell subsets gaining in polyfunctional characteristics.

DOI10.1084/jem.20212169
Alternate JournalJ Exp Med
PubMed ID35604411
PubMed Central IDPMC9130031
Grant ListR37 CA251447 / CA / NCI NIH HHS / United States
T32 CA009110 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
/ CRI / Cancer Research Institute / United States
R01 CA056821 / CA / NCI NIH HHS / United States
P30 CA008748 / NH / NIH HHS / United States